CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies

Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited. Barriers to effective CAR-T cell therapy in treating CTCL include T cell aplasia in a...

Descripción completa

Detalles Bibliográficos
Autores principales: To, Van, Evtimov, Vera J., Jenkin, Graham, Pupovac, Aleta, Trounson, Alan O., Boyd, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433932/
https://www.ncbi.nlm.nih.gov/pubmed/36059451
http://dx.doi.org/10.3389/fimmu.2022.968395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433932/
https://www.ncbi.nlm.nih.gov/pubmed/36059451
http://dx.doi.org/10.3389/fimmu.2022.968395

Ejemplares similares